CARsgen's gastric cancer CAR-T nabs world-first China approval
CARsgen Therapeutics wins NMPA approval for its gastric cancer CAR-T therapy, marking the first such approval worldwide.
CARsgen Therapeutics
Clinical-stage Chinese biotech developing CAR-T cell therapies for solid tumors and hematological malignancies.
Company Info
Upcoming Milestones & Key Dates
2026 H2
Clinical trial
US Phase 2 trial initiation for CT041
2027 H1
Regulatory filing
FDA IND filing for next-gen CAR-T
Clinical Development Pipeline
Zevorcabtagene autoleucel
Target: Claudin18.2 CAR-TCT041
Target: Claudin18.2 CAR-TCT053
Target: BCMA CAR-TRecent News
Leadership Team
Dr. Li Zonghai
Co-founder, Chairman, Chief Executive Officer and Chief Scientific Officer
Dr. Wang Huamao
Co-founder and Chief Operating Officer